Dong Sung Bio Pharm.Co.,Ltd. (002210.KS)
KRW 5320.0
(1.92%)
KRW 5320.0
(1.92%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 596.4 Million KRW | 129.21% |
| 2022 | -2.04 Billion KRW | 61.47% |
| 2021 | -5.29 Billion KRW | -44.36% |
| 2020 | -3.67 Billion KRW | 51.26% |
| 2019 | -7.53 Billion KRW | -316.75% |
| 2018 | -1.8 Billion KRW | -289.22% |
| 2017 | 955.13 Million KRW | 141.72% |
| 2016 | -2.28 Billion KRW | -291.3% |
| 2015 | 1.19 Billion KRW | 165.38% |
| 2014 | -1.83 Billion KRW | 6.92% |
| 2013 | -1.96 Billion KRW | -160.47% |
| 2012 | 3.25 Billion KRW | -9.52% |
| 2011 | 3.59 Billion KRW | 214.27% |
| 2010 | -3.14 Billion KRW | -378.44% |
| 2009 | 1.12 Billion KRW | -29.72% |
| 2008 | 1.6 Billion KRW | -2.66% |
| 2007 | 1.65 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 105.45 Million KRW | 116.43% |
| 2024 Q2 | -1.99 Billion KRW | -1988.47% |
| 2023 Q2 | 136.44 Million KRW | -84.79% |
| 2023 Q1 | 896.95 Million KRW | 612.18% |
| 2023 Q4 | -641.85 Million KRW | -413.31% |
| 2023 FY | 596.4 Million KRW | 129.21% |
| 2023 Q3 | 204.86 Million KRW | 50.14% |
| 2022 Q3 | 1.1 Billion KRW | 148.29% |
| 2022 Q4 | -175.12 Million KRW | -115.87% |
| 2022 FY | -2.04 Billion KRW | 61.47% |
| 2022 Q1 | -1.65 Billion KRW | 38.41% |
| 2022 Q2 | -2.28 Billion KRW | -37.88% |
| 2021 Q3 | -986.69 Million KRW | -227.56% |
| 2021 Q4 | -2.69 Billion KRW | -172.67% |
| 2021 Q1 | -1.32 Billion KRW | 37.39% |
| 2021 Q2 | -301.22 Million KRW | 77.19% |
| 2021 FY | -5.29 Billion KRW | -44.36% |
| 2020 Q1 | -1.28 Billion KRW | 68.12% |
| 2020 FY | -3.67 Billion KRW | 51.26% |
| 2020 Q2 | 1.65 Billion KRW | 229.39% |
| 2020 Q3 | -1.93 Billion KRW | -216.85% |
| 2020 Q4 | -2.1 Billion KRW | -8.84% |
| 2019 Q3 | -1.49 Billion KRW | -20.06% |
| 2019 Q2 | -1.24 Billion KRW | -63.64% |
| 2019 Q1 | -763.16 Million KRW | 37.82% |
| 2019 FY | -7.53 Billion KRW | -316.75% |
| 2019 Q4 | -4.02 Billion KRW | -168.14% |
| 2018 FY | -1.8 Billion KRW | -289.22% |
| 2018 Q2 | -730.92 Million KRW | -351.28% |
| 2018 Q4 | -1.22 Billion KRW | -492.17% |
| 2018 Q1 | -161.96 Million KRW | 81.22% |
| 2018 Q3 | 312.95 Million KRW | 142.82% |
| 2017 FY | 955.13 Million KRW | 141.72% |
| 2017 Q2 | 661.97 Million KRW | 11.53% |
| 2017 Q1 | 593.53 Million KRW | 140.48% |
| 2017 Q4 | -862.62 Million KRW | -253.42% |
| 2017 Q3 | 562.25 Million KRW | -15.06% |
| 2016 Q3 | -855.82 Million KRW | -97.63% |
| 2016 FY | -2.28 Billion KRW | -291.3% |
| 2016 Q4 | -1.46 Billion KRW | -71.33% |
| 2016 Q1 | 465.5 Million KRW | -24.01% |
| 2016 Q2 | -433.04 Million KRW | -193.03% |
| 2015 FY | 1.19 Billion KRW | 165.38% |
| 2015 Q4 | 612.59 Million KRW | 144.59% |
| 2015 Q3 | -1.37 Billion KRW | -327.57% |
| 2015 Q2 | 603.75 Million KRW | 18.09% |
| 2015 Q1 | 511.25 Million KRW | 121.82% |
| 2014 FY | -1.83 Billion KRW | 6.92% |
| 2014 Q2 | 361.94 Million KRW | 1.88% |
| 2014 Q4 | -2.34 Billion KRW | -1043.41% |
| 2014 Q3 | -204.92 Million KRW | -156.62% |
| 2014 Q1 | 355.26 Million KRW | 113.77% |
| 2013 Q1 | 606.13 Million KRW | 132.14% |
| 2013 Q2 | -124.78 Million KRW | -120.59% |
| 2013 Q3 | 34.47 Million KRW | 127.63% |
| 2013 FY | -1.96 Billion KRW | -160.47% |
| 2013 Q4 | -2.57 Billion KRW | -7583.9% |
| 2012 Q4 | -1.88 Billion KRW | -317.52% |
| 2012 Q3 | 867.11 Million KRW | -60.86% |
| 2012 Q2 | 2.21 Billion KRW | 7.71% |
| 2012 Q1 | 2.05 Billion KRW | 0.0% |
| 2012 FY | 3.25 Billion KRW | -9.52% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 3.59 Billion KRW | 214.27% |
| 2011 Q3 | 651.9 Million KRW | -53.49% |
| 2011 Q2 | 1.4 Billion KRW | 0.42% |
| 2011 Q1 | 1.39 Billion KRW | 136.6% |
| 2010 Q3 | 242.23 Million KRW | 7.72% |
| 2010 FY | -3.14 Billion KRW | -378.44% |
| 2010 Q4 | -3.81 Billion KRW | -1674.23% |
| 2010 Q1 | 155.62 Million KRW | 145.37% |
| 2010 Q2 | 224.88 Million KRW | 44.5% |
| 2009 Q3 | 857.75 Million KRW | 149.66% |
| 2009 Q1 | 252.72 Million KRW | 133.99% |
| 2009 FY | 1.12 Billion KRW | -29.72% |
| 2009 Q2 | 343.57 Million KRW | 35.95% |
| 2009 Q4 | -343.02 Million KRW | -139.99% |
| 2008 Q2 | 1.96 Billion KRW | 43.98% |
| 2008 Q1 | 1.36 Billion KRW | 172.27% |
| 2008 FY | 1.6 Billion KRW | -2.66% |
| 2008 Q4 | -743.49 Million KRW | 24.18% |
| 2008 Q3 | -980.59 Million KRW | -149.87% |
| 2007 Q1 | 1.15 Billion KRW | 0.0% |
| 2007 Q4 | -1.88 Billion KRW | -348.2% |
| 2007 FY | 1.65 Billion KRW | 0.0% |
| 2007 Q2 | 1.56 Billion KRW | 35.16% |
| 2007 Q3 | 761.35 Million KRW | -51.32% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -63.606% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 99.224% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 100.75% |
| HANDOK Inc. | 12.57 Billion KRW | 95.259% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 129.983% |
| Yuhan Corporation | 74.56 Billion KRW | 99.2% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 94.665% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 103.306% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 99.735% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | 80.485% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 95.844% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | 38.117% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 97.794% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -63.606% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 107.69% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | 85.214% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 100.853% |
| JW Holdings Corporation | 143.66 Billion KRW | 99.585% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 101.116% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 99.758% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 99.405% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 101.258% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | 91.39% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | 90.783% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | 93.169% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -63.606% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 98.777% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 99.553% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 99.405% |
| Yuhan Corporation | 74.56 Billion KRW | 99.2% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 97.149% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | 80.869% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 98.613% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 99.405% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 97.088% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 98.915% |
| CKD Bio Corp. | -20.15 Billion KRW | 102.959% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 98.15% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 97.643% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 98.166% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 101.258% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 98.201% |
| Boryung Corporation | 68.26 Billion KRW | 99.126% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 101.591% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 95.844% |
| JW Lifescience Corporation | 32.09 Billion KRW | 98.142% |